retatrutide glp-1 gip glucagon receptor agonist Retatrutide—A Game Changer in Obesity Pharmacotherapy What Is Retatrutide (RETA)? The
Description
Weight loss averages 3-5% of body weight
Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis
[(accessed on 21 March 2025)]
GLP-1 therapies like Ozempic have also been shown to lower the risk of heart and kidney disease, leading to additional FDA approvals for heart and kidney protection
So, while Ozempic, Wegovy, and Mounjaros family of drugs are not directly Gila monster venom, their development owes a lot to the natural chemistry of these funky lizards
